Physician profile
Chadi Loutfi
NPI 1831284132
$2,586.89
in general payments reported to CMS, 2019-2025
24 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $134 · 2021: $24.10 · 2022: $221 · 2023: $38.77 · 2024: $488 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,754 · Education: $19.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,753.74 |
| Education | $19.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $387.33 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Insmed, INC. | $287.51 | 2024-2025 | Arikayce, Brinsupri |
| Glaxosmithkline, LLC. | $272.63 | 2019-2025 | Nucala, Trelegy Ellipta |
| Fisher & Paykel Healthcare INC | $197.35 | 2022-2024 | Fisher & Paykel Healthcare |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.90 | 2019-2025 | Ofev, Jascayd |
| Mylan Specialty L.P. | $136.28 | 2019-2020 | |
| Edwards Lifesciences Corporation | $132.21 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $120.29 | 2024-2025 | Uptravi |
| Merck Sharp & Dohme LLC | $117.83 | 2020-2025 | Zerbaxa, Winrevair |
| Novartis Pharmaceuticals Corporation | $111.94 | 2019-2025 | |
| Verona Pharma, INC. | $89.07 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $73.43 | 2021-2025 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $69.55 | 2019-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $67.39 | 2019-2025 | |
| Genzyme Corporation | $64.60 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $53.15 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.65 | 2024 | Glassia |
| E.R. Squibb & Sons, L.L.C. | $36.51 | 2019-2021 | |
| Grifols USA, LLC | $31.61 | 2025 | Prolastin-C Liquid |
| Pfizer INC. | $26.92 | 2019 | |
| Viatris Specialty LLC | $25.92 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $25.68 | 2025 | Purified Cortrophin Gel |
| Amgen INC. | $19.18 | 2025 | Tezspire |
| Lilly USA, LLC | $18.96 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chadi Loutfi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.